Viracta Therapeutics

FDA Gives OK for Viracta’s Phase Ib/II Trial of Oral Combo in Epstein-Barr Virus Tumors
BioSpace
Wed, 07/21/21 - 08:50 pm
Viracta Therapeutics
clinical trials
solid tumors
EBV